Low prostaglandin E2 and cyclooxygenase expression in nasal mucosa fibroblasts of aspirin-intolerant asthmatics

Respirology

Volumn 18, Issue 4, 2013, Pages 711-717

  Roca Ferrer, Jordi ^a,b   Pérez Gonzalez, Maria ^a,b   Garcia Garcia, Francesc J ^a,b   Pereda, Javier ^a,b   Pujols, Laura ^a,b   Alobid, Isam ^a,b,c   Mullol, Joaquim ^a,b,c   Picado, Cesar ^a,b,d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

aspirin intolerance; cyclooxygenase; fibroblast; nasal mucosa; prostaglandin E2

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; ARACHIDONIC ACID;

ADULT; ANIMAL CELL CULTURE; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CHRONIC RHINOSINUSITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NOSE MUCOSA; NOSE POLYP; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; CASE CONTROL STUDY; CELL CULTURE; FLUORESCENCE MICROSCOPY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TIME;

ADULT; ARACHIDONIC ACID; ASTHMA, ASPIRIN-INDUCED; CASE-CONTROL STUDIES; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NASAL MUCOSA; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84876933202     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12076     Document Type: Article

References (29)

1. Stevenson DD, Sczceklik A,. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J. Allergy Clin. Immunol. 2006; 118: 773-786. (Pubitemid 44515109)
2. Picado C,. Mechanisms of aspirin sensitivity. Curr. Allergy Asthma Rep. 2006; 6: 198-202. (Pubitemid 43970986)
3. Stables MJ, Gilroy DW,. Old and new generation lipid mediators in acute inflammation and resolution. Progress Lipid Res. 2011; 50: 35-51.
4. Simmons DL, Botting RM, Hla T,. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004; 56: 387-437. (Pubitemid 39096597)
5. Cowburn AS, Saldek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 1998; 101: 834-846. (Pubitemid 28096081)
6. Adamjee J, Suh YJ, Park HS, et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J. Pathol. 2006; 209: 392-399. (Pubitemid 43997749)
7. Kumlin M, Dalhén B, Björck T, et al. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocation with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am. Rev. Respir. Dis. 1992; 146: 96-103.
8. Picado C, Ramis I, Rosello J, et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am. Rev. Respir. Dis. 1992; 145: 65-69.
9. Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am. J. Respir. Crit. Care Med. 2000; 161: 391-398. (Pubitemid 30129443)
10. Yoshimura T, Yoshikawa M, Otori N, et al. Correlation between the prostaglandin D2/E2 ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. Allergol. Int. 2008; 57: 429-436.
11. Pérez-Novo CA, Watelet JB, Claeys C, et al. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J. Allergy Clin. Immunol. 2005; 115: 1189-1196. (Pubitemid 40824588)
12. Picado C, Fernandez-Morata JC, Juan M, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 1999; 160: 291-296. (Pubitemid 29326102)
13. Pujols L, Mullol J, Alobid I, et al. Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. J. Allergy Clin. Immunol. 2004; 114: 814-819. (Pubitemid 39330251)
14. Roca-Ferrer J, Garcia-Garcia FJ, Pereda J, et al. Reduced expression of COXs and production of prostaglandin E2 in patients with nasal polyps with or without aspirin-intolerant asthma. J. Allergy Clin. Immunol. 2011; 128: 66-72.
15. Adamusiak AM, Stasikowska-Kanicka O, Lewandowska-Polak A, et al. Expression of arachidonate metabolism enzymes and receptors in nasal polyps of aspirin-hypersensitive asthmatics. Int. Arch. Allergy Immunol. 2012; 157: 354-362.
16. 2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J. Allergy Clin. Immunol. 2003; 111: 1041-1048. (Pubitemid 36570865)
17. Casadevall J, Ventura PJ, Mullol J, et al. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55: 921-924.
18. Mullol J, Fernàndez-Morata JC, Roca-Ferrer J, et al. Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps. J. Allergy Clin. Immunol. 2002; 109: 824-830. (Pubitemid 34499517)
19. Demoly P, Crampette L, Lebel B, et al. Expression of cyclo-oxigenases 1 and 2 proteins in upper respiratory mucosa. Clin. Exp. Allergy 1998; 28: 278-283. (Pubitemid 28125911)
20. Owens JM, Shroyer KR, Kingdom TT,. Expression of cyclooxygenase and lypoxygenase enzymes in sinonasal mucosa of patients with cystic fibrosis. Arch. Otolarygol. Head Neck Surg. 2008; 134: 825-831.
21. Roca-Ferrer J, Pujols L, Gartner S, et al. Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax 2006; 61: 592-596. (Pubitemid 44035139)
22. Kang YJ, Mbonye UR, DeLong CJ, et al. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Progress Lipid Res. 2007; 46: 108-125. (Pubitemid 46661865)
23. 2. Trends Immunol. 2004; 25: 40-46. (Pubitemid 38032806)
24. Lee H, Haselkorn T, Borish L, et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007; 132: 1882-1889.
25. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J. Allergy Clin. Immunol. 2005; 116: 970-975. (Pubitemid 41571774)
26. Pierzchalska M, Soja J, Woś M, et al. Deficiency of cyclooxygenases transcripts in cultured primary bronchial epithelial cells of aspirin-sensitive asthmatics. J. Physiol. Pharmacol. 2007; 58: 207-218. (Pubitemid 47026557)
27. Garcia-Garcia FJ, Mullol J, Perez-Gonzalez M, et al. Signal transduction pathways (MAPKs, NF-KB, and C/EBP) regulating COX-2 expression in nasal fibroblasts from asthma patients with aspirin intolerante. PLoS ONE 2012; 7: e51281. doi: 10.1371/journal.pone.0051281.
28. Van Crombruggen K, Van Bruaene N, Holtappels G, et al. Chronic sinusitis and rhinitis: clinical terminology 'Chronic Rhinosinusitis' further supported. Rhinology 2010; 48: 54-58.
29. Fokkens W, Lund V, Mullol J,. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology 2007; 20: 1-136.